nevirapine has been researched along with Exanthema in 70 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Exanthema: Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.
Excerpt | Relevance | Reference |
---|---|---|
"HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation." | 9.17 | Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013) |
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer." | 9.12 | Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007) |
" Risk factors for rash included higher pretreatment CD4 cell count, lower HIV-1 RNA level, female sex, and higher trough nevirapine concentrations." | 9.10 | Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003) |
"We report a case in which an HIV-positive man developed general malaise, skin rash and biochemical hepatitis within days of starting a nevirapine-based antiretroviral treatment regimen." | 7.80 | Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both? ( Helbert, MR; Higgins, SP; Komolafe, AJ; Saxon, CJ, 2014) |
"Drug rash with eosinophilia and systemic symptoms (DRESS Syndrome) associated with nevirapine treatment has not been previously reported in children." | 7.74 | Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. ( Barton, T; Ramilo, O; Santos, RP, 2007) |
"The appearance of rash is one of the most frequent and limiting side-effects during the first 4 weeks of treatment with nevirapine (NVP)." | 6.69 | Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. ( Barreiro, P; Casas, E; de Requena, DG; Estrada, V; González-Lahoz, J; Hoetelmans, R; Jimenéz-Nácher, I; Soriano, V; Téllez, MJ, 2000) |
"HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation." | 5.17 | Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013) |
"Extended nevirapine and cotrimoxazole prophylaxis through 6 months of age among HIV-exposed uninfected infants did not appear to increase the immediate or long-term risk of neutropenia, anemia or skin-rash." | 5.16 | Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated. ( Aizire, J; Bolton, SG; Brown, ER; Coovadia, H; Fowler, MG; Kamateeka, M; Musoke, PM; Shetty, AK; Stranix-Chibanda, L; Wang, J, 2012) |
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer." | 5.12 | Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007) |
" Risk factors for rash included higher pretreatment CD4 cell count, lower HIV-1 RNA level, female sex, and higher trough nevirapine concentrations." | 5.10 | Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003) |
" Women appear to be at an especially high risk for lactic acidosis, nevirapine-associated rashes and hepatotoxicity, and fat redistribution after highly active antiretroviral therapy exposure." | 4.82 | Sex differences in antiretroviral therapy-associated intolerance and adverse events. ( Clark, R, 2005) |
"Nevirapine (NVP) is an effective drug for the treatment of HIV infections, but its use is limited by a high incidence of severe skin rash and liver injury." | 4.12 | Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1. ( Cao, Y; Kurogi, K; Liu, MC; Sakakibara, Y; Segawa, K; Suiko, M; Uetrecht, J, 2022) |
"We report a case in which an HIV-positive man developed general malaise, skin rash and biochemical hepatitis within days of starting a nevirapine-based antiretroviral treatment regimen." | 3.80 | Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both? ( Helbert, MR; Higgins, SP; Komolafe, AJ; Saxon, CJ, 2014) |
" Nevirapine induced rash and SJ syndrome developed within first month of treatment followed by anemia, hepatitis and gastritis which developed within 6 months after initiation of ART." | 3.77 | HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India. ( Anwikar, SR; Bandekar, MS; Kshirsagar, NA; Pazare, AP; Smrati, B; Tatke, PA, 2011) |
"Drug rash with eosinophilia and systemic symptoms (DRESS Syndrome) associated with nevirapine treatment has not been previously reported in children." | 3.74 | Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. ( Barton, T; Ramilo, O; Santos, RP, 2007) |
"NVP pharmacokinetics were modeled by population pharmacokinetic analysis." | 2.77 | Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. ( Aweeka, FT; Currier, JS; Dong, BJ; Frymoyer, A; Hughes, MD; Lizak, P; Lockman, S; Sawe, F; Verotta, D; Zheng, Y, 2012) |
"Rash was more frequent with FD nevirapine, but 88% had no clinical toxicity; elevated AST or ALT levels were transient and resolved spontaneously, suggesting that routine laboratory monitoring has limited value." | 2.75 | Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. ( Burger, D; Chijoka, C; Chintu, C; Cook, A; Ferrier, A; Gibb, DM; Kabamba, D; Kalengo, C; Kankasa, C; Kityo, C; Mulenga, V; Thomason, M; Walker, AS, 2010) |
"Cetirizine has no preventive effect on nevirapine-associated rash." | 2.71 | Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. ( Allaert, FA; Boukli, N; Caumes, E; David, F; Devidas, A; Dupont, B; Launay, O; Lortholary, O; Patey, O; Piketty, C; Prévoteau du Clary, F; Rey, E; Roudière, L; Tréluyer, JM; Urbinelli, R, 2004) |
"Rash is the most frequent adverse event associated with nevirapine." | 2.71 | Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. ( Arranz, A; Arroyo, JA; Blanco, JL; Boix, V; Dalmau, D; De la Torre, J; Domingo, P; Force, L; González, A; Gonzalez, J; Knobel, H; Llibre, JM; Mahillo, B; Miró, JM; Montes, ML; Ribera, E; Rivero, A; Rodriguez, D; Sanz, J; Sarasa, M, 2004) |
" The incidence of rash in the NVP group was significantly higher in female patients with higher CD4 cell counts, while adverse events in the EFV group were not associated with CD4 cell count." | 2.71 | The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. ( Andrews, S; Grinsztejn, B; Lange, JM; Lazanas, MK; Montaner, J; van Leth, F; Wilkins, E, 2005) |
"Rash is the most frequent adverse event associated with nevirapine." | 2.70 | Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. ( Blanco, JL; Boix, V; De Miguel, V; Domingo, P; Force, L; González, A; Knobel, H; Locutura, J; Márquez, M; Miró, JM; Rivero, A; Sanz, J, 2001) |
"The appearance of rash is one of the most frequent and limiting side-effects during the first 4 weeks of treatment with nevirapine (NVP)." | 2.69 | Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. ( Barreiro, P; Casas, E; de Requena, DG; Estrada, V; González-Lahoz, J; Hoetelmans, R; Jimenéz-Nácher, I; Soriano, V; Téllez, MJ, 2000) |
"Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acutely occurring, unpredictable, often life-threatening reactions that are a huge challenge in clinical practice." | 2.58 | [Acute life-threatening drug reactions of the skin]. ( Mockenhaupt, M, 2018) |
"The rash is clearly immune-mediated in rats, and partial depletion of CD4(+) T cells, but not CD8(+) T cells, is protective." | 2.46 | Nevirapine hypersensitivity. ( Abdulla, D; Baban, A; Chen, J; Mannargudi, B; Popovic, M; Shenton, JM; Tharmanathan, T; Uetrecht, JP, 2010) |
"Nevirapine has a long half-life and achieves high steady-state plasma concentrations relative to the concentration required to inhibit 50% viral replication in vitro (IC(50)) in patients." | 2.44 | Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. ( Cooper, CL; van Heeswijk, RP, 2007) |
"The mechanism of drug-induced skin rash is not well understood." | 1.91 | Potential Involvement of Sulfotransferase in the Mechanism of Lamotrigine-induced Skin Rash. ( Bairam, A; Cao, Y; Liu, MC; Uetrecht, J, 2023) |
"Trimethoprim (TMP)-induced skin rash and liver injury are likely to involve the formation of reactive metabolites." | 1.62 | Investigating the Mechanism of Trimethoprim-Induced Skin Rash and Liver Injury. ( Bairam, A; Cao, Y; Jee, A; Liu, M; Uetrecht, J, 2021) |
"Nevirapine (NVP) treatment is associated with a significant incidence of skin rash in humans, and it also causes a similar immune-mediated skin rash in Brown Norway (BN) rats." | 1.39 | 12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash. ( Novalen, M; Sharma, AM; Tanino, T; Uetrecht, JP, 2013) |
"Nevirapine (NVP) can cause serious skin rashes and hepatotoxicity." | 1.39 | Identification of danger signals in nevirapine-induced skin rash. ( Sharma, AM; Uetrecht, J; Zhang, X, 2013) |
"Nevirapine (NVP) treatment is associated with serious skin rashes that appear to be immune-mediated." | 1.39 | Nevirapine bioactivation and covalent binding in the skin. ( Klarskov, K; Sharma, AM; Uetrecht, J, 2013) |
"Nevirapine-based ART was initiated in 820 women and baseline ALT or AST results were abnormal (≥ grade 1) in 113 (14%) women." | 1.36 | Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya. ( Bolu, O; Borkowf, CB; Brooks, JT; Intalapaporn, P; Kiarie, J; McConnell, MS; Mutsotso, W; Peters, PJ; Potter, D; Ratanasuwan, W; Stringer, J; Weidle, PJ; Zulu, I, 2010) |
"In resource-limited settings where nevirapine-containing regimen is the preferred regimen in women, data on severe adverse events (SAEs) according to CD4 cell count are limited." | 1.36 | Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire. ( Abrams, EJ; Amani-Bosse, C; Bédikou, G; Coffie, PA; Dabis, F; Ekouevi, DK; Tanon, AK; Tonwe-Gold, B, 2010) |
"The aim of this study was to measure the cumulative incidence of adverse events (AEs) related to nevirapine in patients switched from efavirenz to immediate full-dose nevirapine (FDN)." | 1.35 | Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. ( Chhneang, V; Fernandez, M; Laureillard, D; Moeung, S; Ngeth, C; Piketty, C; Prak, N; Quillet, C; Riel, V; Song, S, 2008) |
"By logistic regression, history of drug allergy apart from NVP (odds ratio [OR] 11." | 1.35 | Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash. ( Kiertiburanakul, S; Malathum, K; Sathapatayavongs, B; Sungkanuparph, S; Watcharananan, S, 2009) |
"Nevirapine treatment can cause a skin rash." | 1.35 | A study of the specificity of lymphocytes in nevirapine-induced skin rash. ( Chen, X; Gou, H; Mannargudi, B; Tharmanathan, T; Uetrecht, JP, 2009) |
"The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP)." | 1.35 | Oral adverse effects due to the use of Nevirapine. ( Fonseca, LM; Madureira, DF; Mesquita, RA; Moura, MD; Senna, MI, 2008) |
"To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India." | 1.35 | Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. ( Balakrishnan, P; Cecelia, AJ; Devaleenal, B; Flanigan, TP; Kumarasamy, N; Lai, AR; Mayer, KH; Poongulali, S; Saghayam, S; Solomon, S; Venkatesh, KK; Yepthomi, T, 2008) |
"By logistic regression, history of drug allergy (OR, 3." | 1.35 | Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. ( Chantratita, W; Charoenyingwattana, A; Kiertiburanakul, S; Mahasirimongkol, S; Sungkanuparph, S; Sura, T, 2008) |
"In conclusion, NVP-associated skin rashes that lead to NVP discontinuation are common among HIV-infected patients with baseline CD4 <250 cells/microL." | 1.34 | Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL. ( Chaovavanich, A; Chimsuntorn, S; Chottanapund, S; Chumpathat, N; Inthong, Y; Mankatitham, W; Manosuthi, W; Moolasart, V; Prasithsirikul, W; Sittibusaya, C; Sungkanuparph, S; Tansuphaswadikul, S; Termvises, P, 2007) |
"The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study." | 1.33 | Are adverse events of nevirapine and efavirenz related to plasma concentrations? ( Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F, 2005) |
"Nevirapine, used for the treatment of HIV infection, is associated with development of skin rash and liver toxicity." | 1.33 | Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats. ( Caswell, JL; Mannargudi, B; Popovic, M; Shenton, JM; Uetrecht, JP, 2006) |
"Although the skin rash was less evident on rechallenge, microscopically, the cellular infiltrate was more prominent, especially surrounding the hair follicles." | 1.32 | Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. ( Abu-Asab, MS; Shenton, JM; Teranishi, M; Uetrecht, JP; Yager, JA, 2003) |
" Using the recommended lead-in dosing schedule in conjunction with good health care management, this adverse event can be controlled in the vast majority of patients." | 1.32 | Defining the toxicity profile of nevirapine and other antiretroviral drugs. ( Murphy, RL, 2003) |
"Prednisone is commonly used to treat rash, a potentially harmful side effect of nevirapine." | 1.31 | Nevirapine, prednisone and rash. ( , 2000) |
"Severe rash has been observed in 3% of patients taking nevirapine in clinical trials, 85% of whom were men." | 1.31 | Sex differences in nevirapine rash. ( Aberg, JA; Bersoff-Matcha, SJ; Hamrick, HJ; Miller, WC; Mundy, LM; Powderly, WG; van Der Horst, C, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (2.86) | 18.2507 |
2000's | 46 (65.71) | 29.6817 |
2010's | 18 (25.71) | 24.3611 |
2020's | 4 (5.71) | 2.80 |
Authors | Studies |
---|---|
Kurogi, K | 1 |
Cao, Y | 3 |
Segawa, K | 1 |
Sakakibara, Y | 1 |
Suiko, M | 1 |
Uetrecht, J | 6 |
Liu, MC | 2 |
Bairam, A | 2 |
Hasan, M | 1 |
Yunihastuti, E | 1 |
Teguh H, K | 1 |
Abdullah, M | 1 |
Jee, A | 1 |
Liu, M | 1 |
Mockenhaupt, M | 1 |
Sharma, AM | 3 |
Novalen, M | 1 |
Tanino, T | 1 |
Uetrecht, JP | 5 |
Fillekes, Q | 1 |
Mulenga, V | 2 |
Kabamba, D | 2 |
Kankasa, C | 2 |
Thomason, MJ | 1 |
Cook, A | 2 |
Chintu, C | 2 |
Gibb, DM | 2 |
Walker, AS | 2 |
Burger, DM | 1 |
Zhang, X | 1 |
Saxon, CJ | 1 |
Helbert, MR | 1 |
Komolafe, AJ | 1 |
Higgins, SP | 1 |
Sarfo, FS | 1 |
Sarfo, MA | 1 |
Norman, B | 1 |
Phillips, R | 1 |
Chadwick, D | 1 |
Tseng, YT | 1 |
Yang, CJ | 1 |
Chang, SY | 1 |
Lin, SW | 1 |
Tsai, MS | 1 |
Liu, WC | 1 |
Wu, PY | 1 |
Su, YC | 1 |
Luo, YZ | 1 |
Yang, SP | 1 |
Hung, CC | 1 |
Chang, SC | 1 |
Birbal, S | 1 |
Dheda, M | 1 |
Ojewole, E | 1 |
Oosthuizen, F | 1 |
Laureillard, D | 1 |
Prak, N | 1 |
Fernandez, M | 1 |
Ngeth, C | 1 |
Moeung, S | 1 |
Riel, V | 1 |
Chhneang, V | 1 |
Song, S | 1 |
Quillet, C | 1 |
Piketty, C | 2 |
Chen, J | 2 |
Mannargudi, BM | 1 |
Xu, L | 1 |
Chantarangsu, S | 1 |
Mushiroda, T | 1 |
Mahasirimongkol, S | 2 |
Kiertiburanakul, S | 4 |
Sungkanuparph, S | 5 |
Manosuthi, W | 3 |
Tantisiriwat, W | 1 |
Charoenyingwattana, A | 2 |
Sura, T | 2 |
Chantratita, W | 2 |
Nakamura, Y | 1 |
Malathum, K | 1 |
Watcharananan, S | 1 |
Sathapatayavongs, B | 1 |
van Griensven, J | 1 |
Zachariah, R | 1 |
Rasschaert, F | 1 |
Mugabo, J | 1 |
Atté, EF | 1 |
Reid, T | 1 |
Chen, X | 1 |
Tharmanathan, T | 2 |
Mannargudi, B | 3 |
Gou, H | 1 |
Popovic, M | 2 |
Shenton, JM | 3 |
Baban, A | 1 |
Abdulla, D | 1 |
Coffie, PA | 1 |
Tonwe-Gold, B | 1 |
Tanon, AK | 1 |
Amani-Bosse, C | 1 |
Bédikou, G | 1 |
Abrams, EJ | 1 |
Dabis, F | 1 |
Ekouevi, DK | 1 |
Peters, PJ | 1 |
Stringer, J | 1 |
McConnell, MS | 1 |
Kiarie, J | 1 |
Ratanasuwan, W | 1 |
Intalapaporn, P | 1 |
Potter, D | 1 |
Mutsotso, W | 1 |
Zulu, I | 1 |
Borkowf, CB | 1 |
Bolu, O | 1 |
Brooks, JT | 2 |
Weidle, PJ | 2 |
Chijoka, C | 1 |
Ferrier, A | 1 |
Kalengo, C | 1 |
Kityo, C | 1 |
Burger, D | 1 |
Thomason, M | 1 |
Anwikar, SR | 1 |
Bandekar, MS | 1 |
Smrati, B | 1 |
Pazare, AP | 1 |
Tatke, PA | 1 |
Kshirsagar, NA | 1 |
Aizire, J | 1 |
Fowler, MG | 1 |
Wang, J | 1 |
Shetty, AK | 1 |
Stranix-Chibanda, L | 1 |
Kamateeka, M | 1 |
Brown, ER | 1 |
Bolton, SG | 1 |
Musoke, PM | 1 |
Coovadia, H | 1 |
Dong, BJ | 1 |
Zheng, Y | 1 |
Hughes, MD | 1 |
Frymoyer, A | 1 |
Verotta, D | 1 |
Lizak, P | 1 |
Sawe, F | 1 |
Currier, JS | 1 |
Lockman, S | 1 |
Aweeka, FT | 1 |
Eluwa, GI | 1 |
Badru, T | 1 |
Agu, KA | 1 |
Akpoigbe, KJ | 1 |
Chabikuli, O | 1 |
Hamelmann, C | 1 |
Klarskov, K | 1 |
Montaner, JS | 1 |
Cahn, P | 1 |
Zala, C | 1 |
Casssetti, LI | 1 |
Losso, M | 1 |
Hall, DB | 1 |
Wruck, J | 1 |
McDonough, M | 1 |
Gigliotti, M | 1 |
Robinson, PA | 2 |
de Maat, MM | 1 |
ter Heine, R | 1 |
Mulder, JW | 1 |
Meenhorst, PL | 1 |
Mairuhu, AT | 1 |
van Gorp, EC | 1 |
Huitema, AD | 2 |
Beijnen, JH | 2 |
Lackmann, GM | 1 |
Schmidt, B | 1 |
Niehues, T | 1 |
Teranishi, M | 1 |
Abu-Asab, MS | 1 |
Yager, JA | 1 |
Caumes, E | 2 |
Bossi, P | 1 |
Katlama, C | 1 |
Bricaire, F | 1 |
Murphy, RL | 1 |
Boyle, BA | 2 |
Launay, O | 1 |
Roudière, L | 1 |
Boukli, N | 1 |
Dupont, B | 1 |
Prévoteau du Clary, F | 1 |
Patey, O | 1 |
David, F | 1 |
Lortholary, O | 1 |
Devidas, A | 1 |
Rey, E | 1 |
Urbinelli, R | 1 |
Allaert, FA | 1 |
Tréluyer, JM | 1 |
Knobel, H | 4 |
Miró, JM | 3 |
Mahillo, B | 1 |
Domingo, P | 2 |
Rivero, A | 2 |
Ribera, E | 1 |
Gonzalez, J | 1 |
Sanz, J | 2 |
González, A | 3 |
Blanco, JL | 2 |
Boix, V | 2 |
Force, L | 2 |
Llibre, JM | 1 |
Dalmau, D | 1 |
Arroyo, JA | 1 |
De la Torre, J | 1 |
Rodriguez, D | 1 |
Montes, ML | 1 |
Arranz, A | 1 |
Sarasa, M | 1 |
Ananworanich, J | 1 |
Moor, Z | 1 |
Siangphoe, U | 1 |
Chan, J | 1 |
Cardiello, P | 1 |
Duncombe, C | 1 |
Phanuphak, P | 1 |
Ruxrungtham, K | 1 |
Lange, J | 1 |
Cooper, DA | 1 |
Steel-Duncan, JC | 1 |
Pierre, R | 1 |
Gabay, L | 1 |
Christie, CD | 1 |
Hartmann, M | 1 |
Brust, J | 1 |
Schuster, D | 1 |
Mosthaf, F | 1 |
Procaccianti, M | 1 |
Rump, JA | 1 |
Klinker, H | 1 |
Petzoldt, D | 1 |
van Leth, F | 2 |
Andrews, S | 1 |
Grinsztejn, B | 1 |
Wilkins, E | 1 |
Lazanas, MK | 1 |
Lange, JM | 3 |
Montaner, J | 2 |
Kappelhoff, BS | 1 |
MacGregor, TR | 1 |
Baraldi, E | 1 |
Montella, F | 1 |
Uip, DE | 1 |
Thompson, MA | 1 |
Russell, DB | 1 |
Idigbe, EO | 1 |
Adewole, TA | 1 |
Eisen, G | 1 |
Kanki, P | 1 |
Odunukwe, NN | 1 |
Onwujekwe, DI | 1 |
Audu, RA | 1 |
Araoyinbo, ID | 1 |
Onyewuche, JI | 1 |
Salu, OB | 1 |
Adedoyin, JA | 1 |
Musa, AZ | 1 |
Clark, R | 1 |
Daniel, OJ | 1 |
Krain, AB | 1 |
Ogun, SA | 1 |
Odusoga, OL | 1 |
Thongyen, S | 1 |
Chumpathat, N | 2 |
Muangchana, K | 1 |
Caswell, JL | 1 |
Zhou, J | 1 |
Phanupak, P | 1 |
Ditangco, R | 1 |
Kamarulzaman, A | 1 |
Pujary, S | 1 |
Forna, F | 1 |
Liechty, CA | 1 |
Solberg, P | 1 |
Asiimwe, F | 1 |
Were, W | 1 |
Mermin, J | 1 |
Behumbiize, P | 1 |
Tong, T | 1 |
Cooper, CL | 1 |
van Heeswijk, RP | 1 |
Natarajan, U | 1 |
Pym, A | 1 |
McDonald, C | 1 |
Velisetty, P | 1 |
Edwards, SG | 1 |
Hay, P | 1 |
Welch, J | 1 |
de Ruiter, A | 1 |
Taylor, GP | 1 |
Anderson, J | 1 |
Santos, RP | 1 |
Ramilo, O | 1 |
Barton, T | 1 |
Tansuphaswadikul, S | 1 |
Inthong, Y | 1 |
Prasithsirikul, W | 1 |
Chottanapund, S | 1 |
Mankatitham, W | 1 |
Chimsuntorn, S | 1 |
Sittibusaya, C | 1 |
Moolasart, V | 1 |
Termvises, P | 1 |
Chaovavanich, A | 1 |
Moura, MD | 1 |
Senna, MI | 1 |
Madureira, DF | 1 |
Fonseca, LM | 1 |
Mesquita, RA | 1 |
Guelar, A | 1 |
Montero, M | 1 |
Carmona, A | 1 |
Luque, S | 1 |
Berenguer, N | 1 |
Meyssonnier, V | 1 |
Costagliola, D | 1 |
Caumes, PE | 1 |
Wit, FW | 1 |
Kesselring, AM | 1 |
Gras, L | 1 |
Richter, C | 1 |
van der Ende, ME | 1 |
Brinkman, K | 1 |
de Wolf, F | 1 |
Reiss, P | 1 |
De Lazzari, E | 1 |
León, A | 1 |
Arnaiz, JA | 1 |
Martinez, E | 1 |
Negredo, E | 1 |
Clotet, B | 1 |
Storfer, S | 1 |
Asenjo, MA | 1 |
Mallolas, J | 1 |
Gatell, JM | 1 |
Kumarasamy, N | 1 |
Venkatesh, KK | 1 |
Cecelia, AJ | 1 |
Devaleenal, B | 1 |
Lai, AR | 1 |
Saghayam, S | 1 |
Balakrishnan, P | 1 |
Yepthomi, T | 1 |
Poongulali, S | 1 |
Flanigan, TP | 1 |
Solomon, S | 1 |
Mayer, KH | 1 |
Bourezane, Y | 1 |
Salard, D | 1 |
Hoen, B | 1 |
Vandel, S | 1 |
Drobacheff, C | 1 |
Laurent, R | 1 |
Antón, P | 1 |
Soriano, V | 3 |
Jiménez-Nácher, I | 2 |
Rodriguez-Rosado, R | 1 |
Dona, MC | 1 |
Barreiro, PM | 1 |
González-Lahoz, J | 3 |
Dona, C | 1 |
Barreiro, P | 2 |
Casas, E | 1 |
Estrada, V | 1 |
Téllez, MJ | 1 |
Hoetelmans, R | 1 |
de Requena, DG | 1 |
Bersoff-Matcha, SJ | 1 |
Miller, WC | 1 |
Aberg, JA | 1 |
van Der Horst, C | 1 |
Hamrick, HJ | 1 |
Powderly, WG | 1 |
Mundy, LM | 1 |
Lanzafame, M | 1 |
Rovere, P | 1 |
De Checchi, G | 1 |
Trevenzoli, M | 1 |
Turazzini, M | 1 |
Parrinello, A | 1 |
Antinori, A | 1 |
Baldini, F | 1 |
Girardi, E | 1 |
Cingolani, A | 1 |
Zaccarelli, M | 1 |
Di Giambenedetto, S | 1 |
Barracchini, A | 1 |
De Longis, P | 1 |
Murri, R | 1 |
Tozzi, V | 1 |
Ammassari, A | 1 |
Rizzo, MG | 1 |
Ippolito, G | 1 |
De Luca, A | 1 |
Márquez, M | 1 |
De Miguel, V | 1 |
Locutura, J | 1 |
Wong, KH | 1 |
Chan, KC | 1 |
Lee, SS | 1 |
Imperiale, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
Optimal Combination Therapy After Nevirapine Exposure[NCT00089505] | Phase 3 | 745 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
A Cohort Observational Study to Assess the Virologic Response to Standard HIV Treatment in Bamako, Mali[NCT00703404] | 76 participants (Actual) | Observational | 2008-06-18 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
Intervention | Number of Adverse Events (Number) | ||||
---|---|---|---|---|---|
Death | Life-Threatening | Severe | Moderate | Mild | |
Nevirapine | 26 | 87 | 375 | 694 | 832 |
Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
Intervention | participants (Number) | |
---|---|---|
# of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
Nevirapine | 8 | 700 |
Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
Intervention | participants (Number) | |
---|---|---|
# Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
Nevirapine | 26 | 678 |
Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
Intervention | participants (Number) | |
---|---|---|
Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
Nevirapine | 689 | 629 |
Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
Intervention | participants (Number) | |
---|---|---|
# of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
Nevirapine | 16 | 664 |
Placebo | 23 | 663 |
Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 6 |
NVP/LPV_r | 4 |
NoNVP/NVP | 19 |
NoNVP/LPV_r | 26 |
The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 15 |
NVP/LPV_r | 0 |
NoNVP/NVP | 35 |
NoNVP/LPV_r | 0 |
Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 32 |
NVP/LPV_r | 10 |
NoNVP/NVP | 42 |
NoNVP/LPV_r | 50 |
Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.
Intervention | participants (Number) |
---|---|
NVP/NVP | 20 |
NoNVP/NVP | 51 |
Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.
Intervention | cells/mm^3 (Median) | |
---|---|---|
Week 48 CD4 count change from randomization | Week 96 CD4 count change from randomization | |
NoNVP/LPV_r | 172 | 256 |
NoNVP/NVP | 172 | 223 |
NVP/LPV_r | 201 | 278 |
NVP/NVP | 191 | 291 |
Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
Intervention | Percent of participants (Number) | |
---|---|---|
week 48 percent of virologic failure or death | week 96 percent of virologic failure or death | |
NoNVP/LPV_r | 14 | 20 |
NoNVP/NVP | 14 | 17 |
NVP/LPV_r | 4 | 12 |
NVP/NVP | 23 | 31 |
Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
Intervention | percent of participants (Number) | |
---|---|---|
week 48 percent of full adherence in past month | week 96 percent of full adherence in past month | |
NoNVP/LPV_r | 86 | 87 |
NoNVP/NVP | 90 | 93 |
NVP/LPV_r | 88 | 95 |
NVP/NVP | 89 | 94 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.
Intervention | weeks (Number) | ||
---|---|---|---|
5th percentile | 10th percentile | 25th percentile | |
NVP/LPV_r | 60 | 84 | NA |
NVP/NVP | 12 | 12 | 60 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.
Intervention | weeks (Number) | ||
---|---|---|---|
5th percentile | 10th percentile | 25th percentile | |
NoNVP/LPV_r | 12 | 36 | 132 |
NoNVP/NVP | 24 | 36 | NA |
7 reviews available for nevirapine and Exanthema
Article | Year |
---|---|
[Acute life-threatening drug reactions of the skin].
Topics: Allopurinol; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Drug-R | 2018 |
Nevirapine hypersensitivity.
Topics: Animals; Anti-HIV Agents; Biotransformation; Disease Models, Animal; Drug Hypersensitivity; Exanthem | 2010 |
[Antiretroviral-induced toxiderma in HIV-infected patients].
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; | 2003 |
Issues in antiretroviral toxicity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Exanthema; Female; HIV | 2003 |
Sex differences in antiretroviral therapy-associated intolerance and adverse events.
Topics: Acidosis, Lactic; Anti-Retroviral Agents; Didanosine; Exanthema; Female; HIV Infections; Humans; Liv | 2005 |
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Tolerance; Exanthema; HIV Infections; | 2007 |
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Therapy, | 2008 |
16 trials available for nevirapine and Exanthema
Article | Year |
---|---|
Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Exanthema; Female; HIV; HIV Infections; Humans | 2013 |
Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
Topics: Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransfe | 2010 |
Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated.
Topics: Adult; Anemia; Anti-HIV Agents; Blotting, Western; Breast Feeding; Drug Administration Schedule; Dru | 2012 |
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
Topics: Adult; Africa South of the Sahara; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Dru | 2012 |
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
Topics: CD4 Lymphocyte Count; Drug Administration Schedule; Exanthema; Female; HIV; HIV Infections; Humans; | 2003 |
Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.
Topics: Adult; Anti-HIV Agents; Cetirizine; Double-Blind Method; Exanthema; Female; Histamine H1 Antagonists | 2004 |
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.
Topics: Cetirizine; Double-Blind Method; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged | 2004 |
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Dru | 2005 |
[Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Comorbidity; Cyclopropanes; Exanthema; Female; Germany; HIV | 2005 |
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2005 |
Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
Topics: Academies and Institutes; Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort | 2005 |
Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Ind | 2006 |
Safety of nevirapine in pregnancy.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Exanthema | 2007 |
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies | 2008 |
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone | 2000 |
Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study.
Topics: Adult; Double-Blind Method; Drug Hypersensitivity; Exanthema; Female; Humans; Male; Middle Aged; Nev | 2001 |
47 other studies available for nevirapine and Exanthema
Article | Year |
---|---|
Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1.
Topics: Animals; Arylsulfotransferase; Cytosol; Exanthema; HIV Infections; Humans; Isoenzymes; Nevirapine; P | 2022 |
Potential Involvement of Sulfotransferase in the Mechanism of Lamotrigine-induced Skin Rash.
Topics: Drug Eruptions; Exanthema; Humans; Lamotrigine; Nevirapine; Oxides; Sertraline; Sulfates; Sulfotrans | 2023 |
Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Exanthema; | 2022 |
Investigating the Mechanism of Trimethoprim-Induced Skin Rash and Liver Injury.
Topics: Animals; Exanthema; Humans; Liver; Mice; Nevirapine; Rats; Skin; Trimethoprim | 2021 |
12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash.
Topics: Animals; Exanthema; Female; Humans; Molecular Structure; Nevirapine; Rats; Rats, Inbred BN; Time Fac | 2013 |
Identification of danger signals in nevirapine-induced skin rash.
Topics: Animals; Dose-Response Relationship, Drug; Exanthema; Female; Molecular Structure; Nevirapine; Rats; | 2013 |
Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Diagnosis, Differential; Exanthema; Hepatitis; HIV Inf | 2014 |
Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Exanthema; Female; Ghana; Humans; Inci | 2014 |
Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Exanthema; Female; Hepatitis C Antibodies; HIV In | 2014 |
Adverse drug reactions associated with antiretroviral therapy in South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Exanthema; Fema | 2016 |
Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cambodia; Cycl | 2008 |
Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash.
Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Exanthema | 2008 |
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
Topics: Adult; Alleles; Anti-HIV Agents; Case-Control Studies; Exanthema; Female; Genotype; HIV Infections; | 2009 |
Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Chi-Square Distribution; Cohort | 2009 |
Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
Topics: Acidosis, Lactic; Adult; Age Factors; Anti-HIV Agents; Drug Therapy, Combination; Drugs, Generic; Ex | 2010 |
A study of the specificity of lymphocytes in nevirapine-induced skin rash.
Topics: Animals; Cell Proliferation; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2009 |
Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2010 |
Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; CD4 Lymphocyte Count; Chemical | 2010 |
HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
Topics: Alkynes; Anemia; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Live | 2011 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cycloprop | 2012 |
Nevirapine bioactivation and covalent binding in the skin.
Topics: Animals; Exanthema; Female; HIV Infections; Humans; Liver; Mice; Mice, Inbred BALB C; Mice, Inbred C | 2013 |
Nevirapine, prednisone and rash.
Topics: Diphenhydramine; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone | 2000 |
Incidence and risk factors for nevirapine-associated rash.
Topics: Adult; Ambulatory Care; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination | 2003 |
[Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Eruptions; Exanthema; | 2003 |
Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.
Topics: Administration, Oral; Animals; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Disease Models, Ani | 2003 |
Defining the toxicity profile of nevirapine and other antiretroviral drugs.
Topics: Exanthema; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors | 2003 |
Nevirapine-associated rash in a Jamaican child with HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Exanthema; HIV Infections; Humans; Infant; Jama | 2004 |
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Chemical and Drug In | 2005 |
Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Exanthema; Female; HIV Infections; Humans; Nevirapine; Re | 2005 |
Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Exanthema; Female; HIV | 2006 |
Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats.
Topics: Animals; Enzyme-Linked Immunosorbent Assay; Exanthema; Female; Flow Cytometry; Immunohistochemistry; | 2006 |
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, H | 2007 |
Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Child; Drug Hypersensitivity; Eosinophilia; Exanthema; Female; HIV Infections; HIV- | 2007 |
Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Exanthema; Female; HIV Infections; Humans; Incidence; M | 2007 |
Oral adverse effects due to the use of Nevirapine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Burning Mouth Syndrome; CD4 Lymphocyt | 2008 |
Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Exanthema; Female; HI | 2008 |
Nevirapine-associated toxicity in Niger.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Epidemiologic Methods; Exanthema; Fe | 2008 |
Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.
Topics: Adult; Body Weight; Case-Control Studies; CD4 Lymphocyte Count; Developing Countries; Drug Hypersens | 2008 |
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
Topics: Adult; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemica | 2008 |
DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Eosinophil | 1998 |
Incidence of rash and discontinuation of nevirapine using two different escalating initial doses.
Topics: Anti-HIV Agents; Exanthema; HIV Infections; HIV-1; Humans; Incidence; Nevirapine; Reverse Transcript | 1999 |
Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Exanthema; HIV Infections; Hu | 2000 |
Sex differences in nevirapine rash.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Eruptions; Exanthema; Female; HIV Infections; Humans; M | 2001 |
Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Eosinophilia; Exanthema; HIV Infectio | 2001 |
Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.
Topics: Adult; Anti-Allergic Agents; Anti-HIV Agents; Drug Therapy, Combination; Exanthema; Female; HIV Infe | 2001 |
Sex differences in nevirapine rash.
Topics: Anti-HIV Agents; Exanthema; Female; Humans; Male; Nevirapine; Sex Factors | 2001 |
Nevirapine-associated toxicity.
Topics: Anti-HIV Agents; Exanthema; HIV Infections; Humans; Liver Diseases; Nevirapine | 2002 |